[Chronic obstructive lung diseases associated with systemic arterial hypertension]

Area of Science:

• Pulmonology
• Cardiology
• Pharmacology

Context:

• Chronic obstructive pulmonary disease (COPD) affects respiratory function.
• Systemic arterial hypertension presents in various forms, including labile and stable pulmonogenic essential hypertension.
• The interplay between COPD and hypertension impacts disease prognosis and treatment.

Purpose:

• To investigate the clinical course of COPD in patients with normal blood pressure (BP) and different types of systemic arterial hypertension.
• To determine optimal bronchodilator therapy based on the presence and type of hypertension in COPD patients.

Summary:

• Examined 203 patients with COPD and normal BP or hypertension (labile/stable pulmonogenic essential hypertension).
• COPD associated with labile pulmonogenic hypertension and essential hypertension showed a more benign disease course.
• Broncholytic drugs with varying adrenoreceptor action are suitable for COPD with normal BP or labile pulmonogenic hypertension.
• Selective beta-2-adrenoreceptor stimulants, such as salbutamol, are recommended for COPD with stable pulmonogenic hypertension or essential hypertension.

Impact:

• Provides evidence-based recommendations for bronchodilator selection in COPD patients with comorbid hypertension.
• Highlights the influence of hypertension type on COPD prognosis.
• Informs clinical practice for managing complex respiratory and cardiovascular conditions.